On ECHEMI
Home > Drugs > Lattice corneal dystrophy
Lattice corneal dystrophy
Lattice corneal dystrophy is a hereditary corneal disease with symmetrical corneal stroma and severe visual impairment. It was first described by Biber (1890). Haab (1899) and Dimmer (1899) reported some hereditary cases. Fuchs (1902) further confirmed that there is a familial tendency. Bucklers (1938) reported a typical pedigree. In 1967, Kintworth confirmed that this disease is a genetic variation of amyloidosis that is limited to the cornea. At present, five clinical types have been found, namely, I, II, III, IIIA, and IV. Among them, type I is more common, and many cases have been reported in China. Hu Danning summarized that 5 families have been reported in China, with 31 cases. 25 of the 46 offspring of the patient developed the disease, with an incidence rate of 52.9%.
  • Site of disease:

    Eye
  • Infectious :

    Not contagious
  • Frequent population:

    Children under 10 years old
  • Related symptoms:

    Corneal opacity Corneal burns Visual impairment Photophobia and tears Corneal opacity
  • Concurrent disease:

Related Drugs
Levofloxacin Lactate Eye Drops
Indication: It is suitable for the treatment of external eye infections such as bacterial conjunctivitis, keratitis, corneal ulcers, and dacryocystitis.
Manufacturer:

Hangzhou Guoguang Pharmaceutical Co., Ltd.

Ofloxacin Eye Drops
Indication: It is suitable for the treatment of external eye infections such as bacterial conjunctivitis, keratitis, corneal ulcers, dacryocystitis, and postoperative infections.
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.